Canadian biotech drug maker AEterna Zentaris Inc. said Monday that women enrolled in an early stage clinical trial were able to tolerate its experimental cancer treatment.
In the study, 17 women with gynecological and breast cancers were given increasing doses of AN-152, and tolerated the maximum dose of the treatment well, according to the company.
AEterna Zentaris also said that results hinted at effectiveness of the treatment.
The company said that it intends to test the maximum dose of the treatment in a mid-stage clinical trial in women with ovarian and endometrial cancer.
Shares of AEterna Zentaris rose 10 cents to $5.40 in morning trading on the Nasdaq.Copyright 2006 Associated Press